Paul Gosar actually said...

I do not think that what you have put out here in your outlines are suitable for reform.

Do you think that your recommendations to the FDA are sufficient to mitigate this problem?

I think part of our problem--I'm looking here at a drug recall, or a drug-in-stock affidavit as of yesterday.

This is critical mass. It's not just with pharmaceuticals but also our medical devices.